Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Novo Nordisk's diabetes drug

Novo Nordisk has received approval from the US FDA for its type 2 diabetes treatment, Victoza (liraglutide)

Danish pharmaceutical company, Novo Nordisk has announced it has been granted marketing authorisation from the US Food and Drug Administration (FDA) for its type 2 diabetes treatment, Victoza (liraglutide).

Victoza is approved for use in addition to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.

"The US approval of Victoza represents a major advancement in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe." said Lars Rebien Sørensen, president and CEO.

He continued: "We are convinced that Victoza will prove to be a valuable treatment option for people with type 2 diabetes in the US. The ability of Victoza to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."

Novo Nordisk plans to introduce Victoza to the US market within the next few weeks.

26th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics